Analysis of Lyme Disease Lesions

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
Overall Status
Completed
CT.gov ID
NCT00132327
Collaborator
(none)
27
1
159.4
0.2

Study Details

Study Description

Brief Summary

This study will analyze cells from erythema migrans lesions, the "bull's eye" rash of Lyme disease. Little is known about what happens in the skin when it is infected with Borrelia burgdorferi, the bacteria that cause Lyme disease. This study will examine and compare laboratory findings in skin biopsies from people with Lyme disease and from healthy normal volunteers to try to better understand the infection.

Healthy volunteers and people with untreated erythema migrans rash who are 18 years of age or older may be eligible for this study.

All participants undergo a clinical examination, blood tests, between two to four skin biopsies (removal of a small piece of tissue for laboratory examination), and complete two health questionnaires. The biopsies are taken from the erythema migrans lesion in patients with Lyme disease and from skin on the legs, forearms, buttocks, or side from healthy volunteers. To collect the tissue, the skin at the biopsy site is numbed with injection of a local anesthetic and a sharp instrument is then used to remove a round plug of skin about the size of a pencil eraser. The wound may be closed with one or two sutures, or allowed to heal without sutures. The sutures are removed after a week to 10 days.

Patients with Lyme disease receive treatment for their condition. In addition, at the time the sutures are removed and at 4 weeks, 6 months, and 12 months after their first visit they fill out a questionnaire and have additional blood tests.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Little is known of the host and the bacteria response in vivo in patients with Lyme disease. In an attempt to better understand the pathology of erythema migrans (EM), we will use a variety of techniques to characterize patterns in skin biopsies from individuals with a diagnosis of EM and compared those to the patterns seen in biopsies from unaffected individuals. Biopsies from patients may also be evaluated for B. burgdorferi. Patients diagnosed with erythema migrans will have between 2 and 4 punch skin biopsies of affected area, and will return for 4 follow up visits in the course of a year. Therapy for Lyme disease will be offered. Healthy volunteers will have a screening visit, a visit for the skin biopsies and a follow up visit. Patients and healthy volunteers will be compensated for their time and inconvenience.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    27 participants
    Official Title:
    Analysis of Erythema Migrans Lesions
    Study Start Date :
    Aug 17, 2005
    Study Completion Date :
    Nov 29, 2018

    Outcome Measures

    Primary Outcome Measures

      Eligibility Criteria

      Criteria

      Ages Eligible for Study:
      18 Years and Older
      Sexes Eligible for Study:
      All
      Accepts Healthy Volunteers:
      Yes
      • INCLUSION CRITERIA:
      Patients:

      Age greater than or equal to 18 years

      Diagnosis of EM - an expanding annular lesion, at least 5 cm in diameter on a person with a history of exposure to the disease.

      Exposure is defined as having been (less than or equal to 30 days before onset of EM) in wooded, brushy, or grassy areas (i.e., potential tick habitats) in an area in which Lyme disease is endemic.

      A history of tick bite is not required.

      The area of the erythema migrans lesion is suitable for biopsy. This excludes biopsies on the face, neck, scalp, and over the tibia.

      Not know to be positive for RPR, HIV, HBsAg or HCV

      Able to give consent

      Healthy Volunteers:

      Age greater than or equal to 18 years

      Not positive for RPR, HIV, HBsAg or HCV.

      Able to give consent

      EXCLUSION CRITERIA:
      Patients:

      Antibiotic therapy for the current episode of Lyme disease

      Oral corticosteroids within the past 2 weeks

      History of severe skin disease (such as psoriasis, atopic dermatitis) in the last year.

      Diagnosis of diabetes, active cancer, or autoimmune diseases.

      Investigational drugs in the past month

      History of forming large thick scars after skin injuries or surgery

      History of excessive bleeding after cuts or procedures or on anticoagulation.

      Use of steroid cream/ointment at the rash.

      Healthy Volunteers:

      History of Lyme disease, or serological evidence for Lyme disease

      No oral corticosteroids within the past 2 weeks

      History of severe skin disease (such as psoriasis, atopic dermatitis) in the last year.

      Diagnosis of diabetes, cancer, autoimmune diseases.

      Investigational drugs in the past month

      History of forming large thick scars after skin injuries or surgery

      No history of excessive bleeding after cuts or procedures or on anticoagulation.

      Contacts and Locations

      Locations

      Site City State Country Postal Code
      1 National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland United States 20892

      Sponsors and Collaborators

      • National Institute of Allergy and Infectious Diseases (NIAID)

      Investigators

      • Principal Investigator: Adriana R Marques, M.D., National Institute of Allergy and Infectious Diseases (NIAID)

      Study Documents (Full-Text)

      None provided.

      More Information

      Publications

      Responsible Party:
      National Institute of Allergy and Infectious Diseases (NIAID)
      ClinicalTrials.gov Identifier:
      NCT00132327
      Other Study ID Numbers:
      • 050219
      • 05-I-0219
      First Posted:
      Aug 19, 2005
      Last Update Posted:
      Dec 3, 2018
      Last Verified:
      Nov 29, 2018
      Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID)
      Additional relevant MeSH terms:

      Study Results

      No Results Posted as of Dec 3, 2018